Elsevier

Biochemical Pharmacology

Volume 73, Issue 1, 1 January 2007, Pages 147-154
Biochemical Pharmacology

Evidence for significant contribution of a newly identified monoamine transporter (PMAT) to serotonin uptake in the human brain

https://doi.org/10.1016/j.bcp.2006.09.008Get rights and content

Abstract

The high affinity serotonin transporter (SERT) constitutes the principal pathway for removal of serotonin (5-HT) from extracellular fluid of brain, but evidence indicates that other transporters may also be involved in this process. We recently reported the cloning of a novel plasma membrane monoamine transporter (PMAT), which is abundantly expressed in the human brain and avidly transports 5-HT [Engel K, Zhou M, Wang J. Identification and characterization of a novel monoamine transporter in the human brain. J Biol Chem 2004;279:50042–9]. In this study, we evaluated whether PMAT contributes to total human brain uptake of 5-HT using a hybrid depletion approach in Xenopus laevis oocytes. We also examined whether PMAT interacts with selective serotonin reuptake inhibitors (SSRIs) using MDCK cells stably expressing recombinant human PMAT. Microinjection of total human brain poly(A)+ mRNA into oocytes elicited ∼2.5–3-fold increase in 5-HT uptake. Pre-hybridization of poly(A)+ mRNA with PMAT or SERT antisense oligonucleotides significantly reduced mRNA-induced 5-HT uptake. An additive inhibitory effect was observed when poly(A)+ mRNA was co-hybridized with both PMAT and SERT antisense oligonucleotides. In contrast, mRNA-induced 5-HT uptake was not affected by pre-hybridization with sense oligonucleotides. These data suggest that functional transcripts of PMAT are present in the human brain, and the PMAT transporter may be significantly involved in brain uptake of 5-HT. All five tested SSRIs inhibited PMAT with IC50 values ranging from 11 to 116 μM, which are much greater than clinically encountered concentrations, suggesting that PMAT activity is minimally affected by SSRI therapies.

Introduction

Serotonin (5-hydroxytryptamine, 5-HT) is a neurotransmitter in the central nervous system (CNS) that influences a multitude of brain functions, including autonomic function, motor activity, hormone secretion, cognition, and complex processes associated with affection, emotion, and reward [1], [2]. Functional deficiency in 5-HT signaling has been implicated in the pathophysiology of various depressive syndromes [2], [3], [4]. A major goal of antidepressant therapy is to restore 5-HT signaling by elevating extracellular 5-HT levels in the brain [4], [5]. Consequently, genes involved in 5-HT clearance, such as the serotonin reuptake transporter (SERT) and the monoamine oxidases (MAOs), have long been considered as drug targets for the treatment of depression [5], [6]. For example, the widely used selective serotonin reuptake inhibitors (SSRIs) exert their pharmacological effects by specifically blocking SERT-mediated 5-HT reuptake.

Transporter-mediated cellular uptake plays a key role in determining the intensity and duration of 5-HT signaling [4], [7]. Earlier studies suggested that two different transport systems for 5-HT may exist, a high affinity-low capacity process and a low affinity-high capacity process, which are termed uptake1 and uptake2, respectively [8], [9], [10]. The uptake1 system for 5-HT is now known to be mediated by the Na+/Cl-dependent, high affinity transporter, SERT. SERT is primarily expressed in serotonergic neurons and represents the major pathway for presynaptic 5-HT clearance [4], [7]. The low affinity uptake2 system is Na+-independent, displays broad substrate specificity towards monoamine neurotransmitters, and has not been well characterized [8], [11]. Recent cloning work suggests that the uptake2 system may consist of multiple transporters, including members of the organic cation transporters (OCT) family and the plasma membrane monoamine transporter (PMAT) recently identified in our laboratory [12], [13]. These non-SERT transporters may play a role in 5-HT clearance in specific brain regions and/or when extracellular concentrations of 5-HT reach high levels. Uptake2 transporters have also been proposed as potential drug targets for developing antidepression agents with improved efficacy [14].

The human PMAT cDNA encodes a protein of 530 amino acid residues with 11 putative transmembrane domains [12]. When expressed in mammalian cells or Xenopus laevis oocytes, PMAT exhibits typical uptake2 characteristics, mediating Na+-independent, low affinity and high capacity transport of monoamine neurotransmitters [12]. Among the monoamine neurotransmitters, PMAT has the highest affinity towards 5-HT (Km = 114 μM), as compared to dopamine, norepinephrine, and epinephrine (Km ranging from 330 to 15,000 μM) [12]. In cells stably expressing PMAT and SERT, the apparent affinity of recombinant PMAT for 5-HT is much lower than that of SERT (Km, 114 versus 0.5 μM) [12], [15]. However, PMAT also has a much larger transport capacity (Vmax), resulting in roughly comparable uptake efficiencies (Vmax/Km) to SERT in heterologous expression systems [12], [15]. Consistent with its transport function for monoamine neurotransmitters, PMAT mRNA is most strongly expressed in the human brain, and is widely distributed in the CNS [12]. Currently, the in vivo significance of PMAT in brain clearance of 5-HT in humans or intact animals is unknown as most of our previous studies were performed using cDNA transfected heterogenous express systems. In this study, we used an antisense hybrid depletion approach in X. laevis oocytes to investigate the functional significance of PMAT in the brain. This method has been widely used to evaluate the relative importance of a specific transporter to total tissue uptake [16], [17], [18], [19], [20]. Because our data suggested a significant role of PMAT in total brain 5-HT uptake, potential pharmacological interactions between the SSRIs and PMAT have also been investigated.

Section snippets

Chemicals

[3H]5-HT (specific radioactivity, 27.1 Ci/mmol) was from Perkin-Elmer Life Sciences Inc. (Boston, MA). [3H]MPP+ (specific radioactivity, 39.3 Ci/mmol) was from American Radiolabeled Chemicals Inc. (St. Louis, MO). Fluoxetine, paroxetine, and fluvoxamine were from Sigma (St. Louis, MO). Citalopram and sertraline were obtained from Cenrilliant Corporation (Round Rock, TX).

cRNA and mRNA expression in X. laevis oocytes

PMAT cDNA [12] was subcloned into an oocyte expression vector pOX under the control of T3 promoter using Hin dIII and Xba I

Functional expression of PMAT and SERT in oocytes and validation of oligos

PMAT cRNA was synthesized and injected into oocytes. Uptake was performed using [3H]5-HT (1 μM). Compared to water-injected oocytes, oocytes injected with PMAT cRNA exhibited ∼6-fold increase in 5-HT uptake (Fig. 2a). Pre-hybridization of PMAT cRNA with sense oligos (A–C) had no inhibitory effect on PMAT-mediated 5-HT uptake. In contrast, pre-hybridization of cRNA with antisense oligos (A–C) reduced 5-HT uptake levels to those observed in water-injected oocytes (Fig. 2a). These data suggest that

Discussions

In this study, we employed an antisense hybrid depletion approach in X. laevis oocytes to explore the functional significance of a newly cloned monoamine transporter PMAT in the human brain. Previously, the hybrid depletion approach has been used to estimate the relative contribution of a number of individual membrane transporters to tissue-specific uptake of a ligand [16], [17], [18], [19], [20]. This relatively simple and straightforward method allows for the evaluation of gene function in

Acknowledgements

This study was supported by a National Institutes of Health grant GM66233. MZ is supported in part by a predoctoral fellowship from Eli Lilly and Company Foundation. We would like to thank Dr. Randy Blakely at Vanderbilt University for providing the human SERT cDNA.

References (33)

  • R.R. Gainetdinov et al.

    Monoamine transporters: from genes to behavior

    Annu Rev Pharmacol Toxicol

    (2003)
  • G.E. Torres et al.

    Plasma membrane monoamine transporters: structure, regulation and function

    Nat Rev Neurosci

    (2003)
  • K.J. White et al.

    Serotonin transporters: implications for antidepressant drug development

    AAPS J

    (2005)
  • M.B. Youdim et al.

    The therapeutic potential of monoamine oxidase inhibitors

    Nat Rev Neurosci

    (2006)
  • R.D. Blakely et al.

    Molecular physiology of norepinephrine and serotonin transporters

    J Exp Biol

    (1994)
  • L. Iversen

    Neuronal uptake process for amines and amino in acids

    (1970)
  • Cited by (60)

    • The role of stress in health and disease

      2021, A Prescription for Healthy Living: A Guide to Lifestyle Medicine
    • HPLC reveals novel features of nucleoside and nucleobase homeostasis, nucleoside metabolism and nucleoside transport

      2020, Biochimica et Biophysica Acta - Biomembranes
      Citation Excerpt :

      ENT3 also has broad permeant selectivity, and functions intracellularly in lysosomes [6]. ENT4 is found in plasma membranes and transports adenosine and monoamines in the brain and heart [7–9]. With this complexity of distribution and function, it is unclear which of these transporters is/are the most important in nucleoside and nucleobase homeostasis.

    • Comparative analysis of novel decynium-22 analogs to inhibit transport by the low-affinity, high-capacity monoamine transporters, organic cation transporters 2 and 3, and plasma membrane monoamine transporter

      2019, European Journal of Pharmacology
      Citation Excerpt :

      However, tactics have largely focused on combined blockade of DAT, NET, SERT, monoamine receptors, and/or metabolism inhibitors (Moret, 2005; Sambunaris et al., 1997). Current selective reuptake inhibitors for the high-affinity/low-capacity transporters (SERT, NET, DAT) have no appreciable activity at OCT2, OCT3, and PMAT (Emberger et al., 2011; Haenisch and Bönisch, 2010; Matthaeus et al., 2015; Wang et al., 2014; Zhou et al., 2007). Work by us and others support the idea for greater therapeutic potential by blockade of the low-affinity/high-capacity transporter system, in tandem with blockers of high-affinity/low capacity transporters, especially in instances of resistance to high-affinity monoamine transporter therapies (Daws et al., 2013; Hagan et al., 2011; Horton et al., 2013).

    • Pharmacogenomics of bipolar disorder

      2019, Personalized Psychiatry
    • Polyspecific organic cation transporters and their impact on drug intracellular levels and pharmacodynamics

      2016, Pharmacological Research
      Citation Excerpt :

      In the kidney, MATE2 and MATE2-K are also restricted to the apical membrane of renal proximal tubule cells [45]. PMAT mRNA is most strongly expressed in the brain; but lower levels of expression are also found in heart, small intestine, kidney, and liver [11,46,47]. In the brain, PMAT transcripts are widely distributed in many brain regions and are particularly abundant in brain cortex, hippocampus, cerebellum and epithelial cells of the choroid plexus [11,48].

    View all citing articles on Scopus
    1

    Present address: Merck KGaA, Institute of Drug Metabolism and Pharmacokinetics, Am Feld 32, D-85567 Grafing, Germany.

    View full text